Patient-Derived Xenografts to Reduce Cancer Health Disparities
NCT04410302
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Bladder Carcinoma
- Gastric Carcinoma
- Liver and Intrahepatic Bile Duct Carcinoma
- Lung Carcinoma
- Malignant Neoplasm
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 21 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, Davis
- Last updated on ClinicalTrials.gov
- August 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, CA
- University of California Davis Comprehensive Cancer Center · Sacramento, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.